ACC 2026: Meta-analysis supports CagriSema as superior first-line therapy in obesity

KOLs note that CagriSema could cannibalise semaglutide's market share in obesity due to its improved efficacy.
MedPage Today on MSN

Are Bayesian statistics coming to a clinical trial near you?

What physicians should know about FDA's new proposed guidance ...
Regulatory Affairs Professionals Society

This Week at FDA: Reactions to FDA’s Bayesian methods guidance, GDUFA science report, and more

Welcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug, and medical device regulation and what we’re reading from around the web. This week, ...

PhaseV Bringing Integrated AI for Faster Clinical Trials to the Global Stage

BOSTON, March 26, 2026 /PRNewswire/ -- PhaseV, a leader in AI/ML for clinical development, today announced its spring and summer 2026 conference schedule. PhaseV's leadership will demonstrate how the ...